Health News: Innovador enfermedad de ojo seco candidato a fármaco 'RCI1001' regains spotlight
'RCI001,' which inhibits Rac1, a cell signaling molecule, is a patented compuesto that improves the major symptoms of enfermedad de ojo seco including inflammation control, minimal eye irritation, and rapid recovery of epitelio corneal.
Actualmente, steroid eye drops are used in various enfermedades de la superficie ocular including tratamiento de la enfermedad de ojo secos. Steroid eye drops have excellent antiinflamatorio effects and provide superior short-term eficacia compared to other medications, but their long-term use is limited in actual clinical settings due to efectos secundarios such as increased presión intraocular and cataracts.
En este estudio, Professor Kim's team confirmó the inhibitory effects of 'RCI001' on 'Rac1' and 'NLRP3 inflammasome (an inflammation-inducing immune protein).' First, topical tratamiento with 'RCI001' in an immune-overactivated LPS (Lipopolysaccharide) mouse model confirmó suppression of Rac1 expression and reduction of inflammatory cytokine expression.
In an alkali-induced mouse eye injury model, 'RCI001' showed faster daño corneal recovery compared to conventional steroid formulacións. Además, it demostró reduced transcription and protein expression of Rac1 signaling molecules and the inflammatory complex 'NLRP3' in the corneal tissue of this model.